EyePoint, Inc. EYPT
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E technology (Durasert E) for sustained intraocular drug delivery. The Company's lead product candidate, DURAVYU1, is an investigational sustained delivery treatment for vascular endothelial growth factor (VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI) with the Company's bioerodible Durasert E drug delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials (LUGANO and LUCIA) for wet age-related macular degeneration (wet AMD) and in Phase 3 clinical trials (COMO and CAPRI) for diabetic macular edema (DME). Additional pipeline programs include EYP-2301, razuprotafib, a TIE-2 agonist, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EyePoint is headquartered in Watertown, Massachusetts with a commercial manufacturing facility in Northbridge, Massachusetts.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- Country US
- China
- Other
| Region | FY2025 | FY2024 |
|---|---|---|
| Country US | $30.0M | $42.0M |
| China | $1.3M | $1.1M |
| Other | $100.0K | $100.0K |
As the company reported it, from the “Segment and Geographic Area Information - Summary of Company's Revenues and Long-Lived Assets, Net, by Geographic Area (Detail)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.4M | $43.3M | $46.0M | $41.4M | $36.9M | $34.4M | $20.4M | $3.0M | $7.5M | $1.6M |
| R&D | $221.0M | $132.9M | $64.7M | $49.6M | $28.5M | $17.4M | $15.4M | $16.2M | $14.9M | $14.4M |
| SG&A | $51.6M | $52.4M | $40.1M | $34.8M | $25.6M | $20.7M | $17.9M | $11.5M | $11.2M | $9.0M |
| Total operating expenses | $274.8M | $189.1M | $121.1M | $141.0M | $92.2M | $71.7M | $68.2M | $29.2M | $26.1M | $23.4M |
| Operating income | -$243.4M | -$145.9M | -$75.1M | -$99.6M | -$55.3M | -$37.3M | -$47.9M | -$26.3M | -$18.6M | -$21.8M |
| Interest expense | $33.0K | $14.0K | $1.2M | $3.2M | $5.5M | $7.3M | $6.2M | $720.0K | $0 | $0 |
| Pre-tax income | -$231.7M | -$130.8M | -$70.7M | -$102.3M | -$58.4M | -$45.4M | -$56.8M | -$53.2M | -$18.5M | -$21.7M |
| Income tax | $279.0K | $90.0K | $83.0K | $0 | $0 | $0 | $0 | $0 | $0 | $155.0K |
| Net income | -$232.0M | -$130.9M | -$70.8M | -$102.3M | -$58.4M | -$45.4M | -$56.8M | -$53.2M | -$18.5M | -$21.5M |
| EPS, basic | -3.17 | -2.32 | -1.82 | -2.74 | -2.03 | — | — | — | -0.52 | -0.68 |
| EPS, diluted | -3.17 | -2.32 | -1.82 | -2.74 | -2.03 | -3.54 | -5.44 | -1.15 | -0.52 | -0.68 |
| Shares, diluted (wtd. avg.) | 73,251 | 56,298 | 38,904 | 37.3M | 28.8M | — | — | — | 35.3M | 31.6M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $101.8M | $99.7M | $281.4M | $95.8M | $178.7M | $45.1M | $22.4M | $45.4M | $17.0M | $15.5M |
| Short-term investments | $204.3M | $271.2M | $49.8M | $48.9M | $33.0M | $0 | — | — | — | $13.7M |
| Inventory | $1.8M | $2.3M | $3.9M | $2.9M | $3.6M | $5.3M | $2.1M | $279.0K | $0 | — |
| Total current assets | $328.7M | $383.3M | $344.8M | $172.8M | $237.7M | $63.1M | $41.7M | $47.6M | $17.7M | $30.0M |
| Property, plant and equipment | $9.0M | $8.2M | $5.3M | $1.4M | $476.0K | $630.0K | $357.0K | $288.0K | $313.0K | $290.0K |
| Other intangibles | — | — | — | $0 | $22.7M | $25.2M | $27.7M | $30.1M | $364.0K | $1.1M |
| Total assets | $364.0M | $418.5M | $355.2M | $180.4M | $263.4M | $91.7M | $73.0M | $78.2M | $18.7M | $31.6M |
| Accounts payable | $10.5M | $11.7M | $6.5M | $5.9M | $7.4M | $4.8M | $4.2M | $2.6M | $1.0M | $1.4M |
| Short-term debt | — | — | $0 | $10.5M | $0 | — | — | — | — | — |
| Total current liabilities | $37.0M | $49.0M | $63.3M | $34.5M | $23.7M | $14.9M | $11.5M | $21.5M | $5.3M | $5.1M |
| Long-term debt | — | — | — | $29.3M | $36.6M | $38.0M | $47.2M | $17.6M | $0 | — |
| Total liabilities | $57.9M | $82.0M | $88.9M | $84.0M | $79.0M | $73.2M | $64.6M | $40.5M | $5.3M | $10.7M |
| Retained earnings | -$1.10B | -$873.0M | -$742.1M | -$671.4M | -$569.1M | -$510.7M | -$465.3M | -$408.5M | -$310.8M | -$292.2M |
| Total equity | $306.1M | $336.5M | $266.3M | $96.4M | $184.4M | $18.5M | $8.3M | $37.6M | $13.3M | $20.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$240.1M | -$126.2M | $1.9M | -$65.0M | -$50.1M | -$14.4M | -$56.7M | -$21.9M | -$20.5M | -$16.3M |
| Depreciation and amortisation | $2.3M | $1.5M | $464.0K | $396.0K | $311.0K | $189.0K | $144.0K | $167.0K | $91.0K | $152.0K |
| Stock-based compensation | $27.9M | $36.7M | $12.1M | $14.2M | $7.4M | $5.5M | $4.6M | $2.7M | $2.5M | $2.2M |
| Capital expenditure | $3.3M | $4.1M | $3.5M | $2.1M | $156.0K | $362.0K | $213.0K | $108.0K | $147.0K | $113.0K |
| Investing cash flow | $68.6M | -$219.4M | -$3.3M | -$17.3M | -$33.1M | -$362.0K | -$213.0K | -$16.9M | $13.6M | -$4.5M |
| Financing cash flow | $173.6M | $164.0M | $187.1M | -$690.0K | $216.9M | $37.5M | $33.9M | $60.7M | $8.5M | $17.0M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-182035.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $7.5M | $3.0M | $20.4M | $34.4M | $36.9M | $41.4M | $46.0M | $43.3M | $31.4M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$21.5M | -$18.5M | -$53.2M | -$56.8M | -$45.4M | -$58.4M | -$102.3M | -$70.8M | -$130.9M | -$232.0M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Results announced Item 2.02
- Other event Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| A | AGILENT TECHNOLOGIES, INC. | $48.79B | 37.9x | 6.7% |
| WAT | WATERS CORP /DE/ | $44.57B | 42.2x | 7.0% |
| ILMN | ILLUMINA, INC. | $40.68B | 49.4x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $33.47B | 39.7x | 4.0% |
| RVTY | REVVITY, INC. | $17.72B | 76.7x | 3.7% |
| AVTR | Avantor, Inc. | $11.80B | — | -3.4% |
| BIO | BIO-RAD LABORATORIES, INC. | $9.89B | 13.3x | 0.7% |
| TXG | 10x Genomics, Inc. | $9.30B | — | 5.2% |